Artificial Intelligence in Oncology Research Report 2024-2035: Global Market to Grow by $8 Billion as a CAGR of 21.4% - Industry Stakeholders are Actively Upgrading their Existing AI Capabilities
March 18, 2025 05:09 ET
|
Research and Markets
Dublin, March 18, 2025 (GLOBE NEWSWIRE) -- The "Artificial Intelligence in Oncology Market Industry Trends and Global Forecasts to 2035, by Type of Cancer, Type of End-Users and Key Geographical...
Advocates Rallied in Record Numbers for Call-on Congress 2025
March 13, 2025 14:00 ET
|
Fight Colorectal Cancer
Washington D.C., March 13, 2025 (GLOBE NEWSWIRE) -- Fight Colorectal Cancer (Fight CRC), the nation’s leading advocacy organization dedicated to ending colorectal cancer, brought together more than...
27,400 Reasons to Pay Attention: United in Blue Demands Action
March 03, 2025 15:24 ET
|
Fight Colorectal Cancer
Springfield, Mo., March 03, 2025 (GLOBE NEWSWIRE) -- March is Colorectal Cancer Awareness Month, and Fight Colorectal Cancer (Fight CRC) is strengthening its awareness efforts with the fourth United...
Interventional Oncology Research Report 2025: Devices & Consumables, Procedures, Cancer, End User Market Analysis and Forecasts 2024-2029
February 27, 2025 11:08 ET
|
Research and Markets
Dublin, Feb. 27, 2025 (GLOBE NEWSWIRE) -- The "Interventional Oncology Market by Devices & Consumables (RF, Microwave, Cryoablation. Embolization), Procedures (Thermal Ablation, Non-Thermal...
Persephone Biosciences Announces Full Enrollment in AMBROSIA Food as Medicine Study
January 28, 2025 09:00 ET
|
Persephone Biosciences, Inc.
Persephone Biosciences Announces Full Enrollment in AMBROSIA Food as Medicine Study
Cancer Biopsy Market Size is Expected to Reach USD 60.92 Billion by 2033, Growing at a CAGR of 7.81%: Straits Research
January 20, 2025 10:35 ET
|
Straits Research Private Limited - Garner Insights
New York, United States, Jan. 20, 2025 (GLOBE NEWSWIRE) -- A biopsy is a procedure where a small amount of tissue is extracted for examination under a microscope. In the case of a core biopsy,...
Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate
January 08, 2025 08:00 ET
|
Compass Therapeutics
Top-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with biliary tract cancer (BTC) is on track for end of Q1 2025.CTX-10726 (a novel PD-1 x...
Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
December 17, 2024 07:00 ET
|
Immunocore Holdings plc
The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with standards of care, in patients with advanced cancers expressing PIWIL1 First...
Enterome Presents Encouraging Initial Clinical Data on EO4010 in Colorectal Cancer at ESMO IO 2024
December 11, 2024 06:00 ET
|
Enterome
Data from the ongoing Phase 2 of EO4010 demonstrate tumor target specific immune responses and objective tumor responses, including in liver mets, in patients with previously treated microsatellite...
AmMax Bio and MD Anderson Announce Agreements to Advance Development of AMB-066 in Colorectal Cancer Patients with Minimal Residual Disease
December 10, 2024 08:00 ET
|
AmMax Bio, Inc.
AmMax Bio and MD Anderson to Advance Development of AMB-066 in Colorectal Cancer Patients with Minimal Residual Disease